GL Ventures, a venture capital firm, and Temasek, a Singaporean holding company, led a $230m Series C funding round in Clover Biopharmaceuticals, a global clinical-stage biotechnology company. The round was joined by Oceanpine Capital, OrbiMed and Delos Capital. "Our goal has always been to bring our innovative vaccines and biologic therapies to the world by leveraging our proprietary Trimer-Tag© platform technology, state-of-the art cGMP biomanufacturing capabilities, and passionate team of over 500 scientists, experienced industry professionals and advisors. We look forward to using the proceeds from this financing round to accelerate development of our pipeline, expand our in-house R&D and biomanufacturing capabilities and move closer to our mission of improving the quality of life and wellbeing for patients around the world," Joshua Liang, Clover CEO and Board Director.